Literature DB >> 25722211

A Murine Model for Metastatic Conjunctival Melanoma.

Nadine E de Waard1, Jinfeng Cao2, Sean P McGuire3, Paraskevi E Kolovou3, Ekaterina S Jordanova4, Bruce R Ksander3, Martine J Jager1.   

Abstract

PURPOSE: Conjunctival melanoma (CM) is an ocular malignancy with a high rate of local recurrences after treatment, and can give rise to deadly metastases. The establishment of a murine model will further our understanding of this disease and allow in vivo testing of new therapies. We therefore analyzed the ability of three CM cell lines to grow orthotopically and spread to distant sites. Furthermore, we determined the characteristics of the xenografts and their metastases.
METHODS: Orthotopic xenografts of human CM were established by subconjunctival injection of three different CM cell lines into NOD/SCID IL2 rγnull mice. Single-cell suspensions were generated from the primary tumors and placed subconjunctivally in another set of mice, which were then screened for metastases. The presence of melanoma markers was determined on the cell lines and during tumor development.
RESULTS: Subconjunctival injection of cultured CM cells into immunodeficient mice led to excellent subconjunctival tumor growth in all inoculated mice (n = 101) within 2 weeks; however, no metastases were found at the time of autopsy. Serial in vivo passage of primary tumor cells resulted in metastatic tumors in the draining lymph nodes (n = 21). The CM cell lines, as well as the tumor xenografts and their metastases, were positive for the melanoma markers HMB-45, S100B, and MART-1. Two cell lines and their corresponding xenografts carried a BRAF mutation, the third showed an NRAS mutation.
CONCLUSIONS: We established a murine model for CM that shows excellent formation of metastases in a pattern that accurately resembles metastatic human CM following in vivo passaging.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25722211     DOI: 10.1167/iovs.14-15239

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  Expression of Multidrug Resistance Transporter ABCB5 in a Murine Model of Human Conjunctival Melanoma.

Authors:  Nadine E de Waard; Paraskevi E Kolovou; Sean P McGuire; Jinfeng Cao; Natasha Y Frank; Markus H Frank; Martine J Jager; Bruce R Ksander
Journal:  Ocul Oncol Pathol       Date:  2015-04

2.  IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma.

Authors:  Dawei Song; Sonia Cismas; Caitrin Crudden; Eric Trocme; Claire Worrall; Naida Suleymanova; Tingting Lin; Huiyuan Zheng; Stefan Seregard; Ada Girnita; Leonard Girnita
Journal:  Oncogene       Date:  2021-11-17       Impact factor: 9.867

3.  Process development and safety evaluation of ABCB5+ limbal stem cells as advanced-therapy medicinal product to treat limbal stem cell deficiency.

Authors:  Alexandra Norrick; Jasmina Esterlechner; Elke Niebergall-Roth; Markus H Frank; Mark A Kluth; Ulf Dehio; Samar Sadeghi; Hannes M Schröder; Seda Ballikaya; Nicole Stemler; Christoph Ganss; Kathrin Dieter; Ann-Kathrin Dachtler; Patrick Merz; Saadettin Sel; James Chodosh; Claus Cursiefen; Natasha Y Frank; Gerd U Auffarth; Bruce Ksander
Journal:  Stem Cell Res Ther       Date:  2021-03-19       Impact factor: 6.832

4.  Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy.

Authors:  Martine J Jager; Robert M Verdijk; Jinfeng Cao; Renier C Heijkants; Aart G Jochemsen; Mehmet Dogrusöz; Mark J de Lange; Pieter A van der Velden; Sjoerd H van der Burg
Journal:  Oncotarget       Date:  2016-07-22

5.  The Use of Panitumumab-IRDye800CW in a Novel Murine Model for Conjunctival Squamous Cell Carcinoma.

Authors:  Gun Min Youn; Ayden G Case; Trent Jarin; BaoXiang Li; Aditi Swarup; Andrea Naranjo; Charbel Bou-Khalil; Jacqueline Yao; Quan Zhou; Marisa E Hom; Eben L Rosenthal; Albert Y Wu
Journal:  Transl Vis Sci Technol       Date:  2022-07-08       Impact factor: 3.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.